Vera Therapeutics (VERA) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company milestones and leadership

• Achieved first drug approval in July and launched commercial operations, with first earnings call scheduled for November to provide deeper insights into launch progress.

• Led a paradigm shift in nephrology by aligning with FDA and experts on new trial analysis methods, accelerating timelines for full approval.

• Positioned as a leader in nephrology, aiming to maintain leadership and strong commercial traction over the next year.

Clinical data and regulatory alignment

• Trutakna targets the root cause of IgA nephropathy, showing a 46% reduction in proteinuria and stable kidney function over two years.

• Phase III trials include composite kidney progression endpoints, with final efficacy readout and GFR data expected this quarter.

• FDA review documents revealed stabilization of GFR through 72 weeks, supporting the drug's kidney-protective profile.

• Subgroup analyses showed consistent benefit across age, sex, region, and baseline characteristics.

Commercial strategy and market opportunity

• Launched at $425,000 per year, with no significant payer pushback and a broad label without proteinuria threshold.

• Targeting 6,000 of 11,000 U.S. nephrologists with an 82-rep sales force, 90% of whom have rare disease and nephrology experience.

• Patient hub (TRU SUPPORT) and specialty pharmacy distribution streamline access and support for physicians and patients.

• Over 70% of diagnosed patients are commercially insured, reflecting a favorable payer mix.